India’s Covid-19 vaccine: Covaxin’s animal trial gets robust immune responses, says Bharat Biotech

Vastavam Web: In the wake of many researchers and pharma giants across the globe upping their game to come up with a potential vaccine to cure the pandemic, Bharat Biotech announced that the Animal trials in Phase I clinical trials are quite impressive. The drug development firm headquartered in Hyderabad took to Micro-blogging site Twitter and said they are proud to announce the results of the animal trials of the COVAXIN.

Hyderabad-based Bharat Biotech on Friday released study results of its Covid-19 vaccine candidate Covaxin, which is currently in Phase I/II human trials. The results show reduction in replication of the virus in the nasal cavity, throat and lung tissues of monkeys. “These results demonstrate the protective efficacy in a live viral challenge model,” said Bharat Biotech.

Bharat Biotech proudly announces the animal study results of COVAXIN – These results demonstrate the protective efficacy in a live viral challenge model,” the firm’s Tweet read. Bharat Biotech and the Indian Council of Medical Research (ICMR) joined hands to manufacture a vaccine named COVAXIN. 12 Institutions across India were picked to carry out the clinical trials.

A tw-dose vaccination regimen of inactivated SARS-CoV-2 vaccine candidates was administered in 20 rhesus macaques (divided into four groups equally).

One group was administered with placebo, while three groups were immunized with 3 different vaccine candidates at 0 and 14 days. All the macaques were exposed to viral challenge 14 days after the 2nd dose. The results showed protective efficacy, increasing SARS-CoV-2 specific IgG and neutralizing antibodies, reducing replication of the virus in the nasal cavity, throat, and lung tissues of monkey.

No evidence of pneumonia was observed by histopathological examination in vaccinated groups, unlike the placebo group, the company said.